Clinical Trial Detail

NCT ID NCT01963481
Title Exemestane and Cyclophosphamide for Metastatic Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements yes
Sponsors New York University School of Medicine
Indications

Her2-receptor negative breast cancer

Therapies

Cyclophosphamide

Exemestane

Age Groups: adult

Additional content available in CKB BOOST